Wicart C

Medical Affairs, Johnson&Johnson,

6 papers · ORCID

ArticleKetamine

Patient reported outcomes of MDD patients treated with esketamine nasal spray in real world practice: the French ELLIPSE study

Llorca P, Samalin L, Olié E +4

Europe PMC2026
ArticleKetamine

Real-world clinical practice, effectiveness and safety of esketamine nasal spray in major depressive disorder patients: a French prospective cohort (ELLIPSE study).

Llorca PM, Sauvaget A, Olié E +12

Europe PMC2026
ArticleKetamine

Effectiveness and factors associated with esketamine response during the 4-week induction period for treatment-resistant depression: post-hoc analysis of the real-world ESKALE study.

Samalin L, Rothärmel M, Mekaoui L +6

Europe PMC2026
ArticleKetamine

Real world clinical practice, efficacy and safety of esketamine nasal spray in MDD patients: the French ELLIPSE study

Llorca P, Mékaoui L, Rotharmel M +4

Europe PMC2025
ArticleKetamine

Use of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression in Routine Practice: A Real-World French Study.

Samalin L, Mekaoui L, Rothärmel M +5

Europe PMC2024
ArticleKetamine

Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray.

Samalin L, Mekaoui L, De Maricourt P +5

Europe PMC2024